Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., Van den Eynde, M., Di Bartolomeo, M., … Yoshino, T. (2023). Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Raghav, Kanwal Pratap Singh, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Maria Di Bartolomeo, Yoshito Komatsu, et al. “Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Raghav KPS, Siena S, Takashima A, Kato T, Van den Eynde M, Di Bartolomeo M, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Raghav, Kanwal Pratap Singh, et al. “Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Raghav KPS, Siena S, Takashima A, Kato T, Van den Eynde M, Di Bartolomeo M, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Strickler JH, Barrios D, Yan Q, Kamio T, Kobayashi K, Yoshino T. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. JOURNAL OF CLINICAL ONCOLOGY. 2023.